MediWound Ltd
MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The company develops, produces, and commercializes biologics that improve patient care, reduce costs, and minimize unnecessary surgeries. Their key products include NexoBrid®, EscharEx®, and MW005, which are in various stages of clinical development and approval for treating burns, chronic wounds, and skin cancers. MediWound collaborates with strategic partners worldwide, supported by governmental agencies like BARDA, and maintains a strong focus on innovation, quality, and expanding access to advanced wound care solutions. The company also emphasizes a talented leadership team and a dedicated workforce committed to transforming healthcare.
Industries
Nr. of Employees
medium (51-250)
MediWound Ltd
42 Hayarkon Street, Yavne 8122745, Israel
Patents
Proteolytic extract from bromelain for the treatment of connective tissue disorders
US-10293033-B2
View DetailsProteolytic extract from bromelain for the treatment of connective tissue disorders
US-9511126-B2
View Details
Proteolytic extract from bromelain for the treatment of connective tissue disorders
US-10293033-B2
View DetailsProteolytic extract from bromelain for the treatment of connective tissue disorders
US-9511126-B2
View DetailsProducts
NexoBrid
Topically applied biologic concentrate of proteolytic enzymes for selective removal of burn eschar in deep partial- and full-thickness thermal burns; single short-duration bedside applications in many cases.
EscharEx
Topical bioactive concentrate of proteolytic enzymes enriched in bromelain for debridement of chronic and hard-to-heal wounds (e.g., venous leg ulcers, diabetic foot ulcers), under global Phase III evaluation.
MW005
Topical enzymatic biological formulation under clinical development for treatment of low-risk non-melanoma skin cancers such as basal cell carcinoma; based on the same proteolytic enzyme active substance as other pipeline products.
NexoBrid
Topically applied biologic concentrate of proteolytic enzymes for selective removal of burn eschar in deep partial- and full-thickness thermal burns; single short-duration bedside applications in many cases.
EscharEx
Topical bioactive concentrate of proteolytic enzymes enriched in bromelain for debridement of chronic and hard-to-heal wounds (e.g., venous leg ulcers, diabetic foot ulcers), under global Phase III evaluation.
MW005
Topical enzymatic biological formulation under clinical development for treatment of low-risk non-melanoma skin cancers such as basal cell carcinoma; based on the same proteolytic enzyme active substance as other pipeline products.
Services
Production and supply of biologic topical products to commercial partners under exclusive license and supply contracts.
Operational and research collaborations with third parties to run multinational Phase II/III studies and to provide adjunctive study materials and logistical support.
Management of multi-channel global distribution, including direct sales, local sales representatives and distributors for product launches and market expansion.
Production and supply of biologic topical products to commercial partners under exclusive license and supply contracts.
Operational and research collaborations with third parties to run multinational Phase II/III studies and to provide adjunctive study materials and logistical support.
Management of multi-channel global distribution, including direct sales, local sales representatives and distributors for product launches and market expansion.
Expertise Areas
- Enzymatic therapeutic development
- Topical biologic formulation and stability
- Wound care and non-surgical debridement
- Clinical trial management (RCTs, adaptive designs, multicenter and pediatric studies)
Key Technologies
- Proteolytic enzyme APIs enriched in bromelain
- Topical biologic drug formulation
- Temperature-stable topical formulations
- Aseptic sterile processing (cGMP)
News & Updates
MediWound announced financial results for Q1 2025 and provided a corporate update.
The company announced it will present scientific abstracts at the Wound Healing Society and SAWC Spring 2025.
Financial results for 2024 and corporate updates were announced.
The company announced the start of a global Phase III trial for EscharEx® targeting VLUs.
The FDA approved NexoBrid® for eschar removal in adults with severe burns.
EMA has validated for review the application to expand NexoBrid® indication to pediatric patients.
MediWound announced financial results for Q1 2025 and provided a corporate update.
The company announced it will present scientific abstracts at the Wound Healing Society and SAWC Spring 2025.
Financial results for 2024 and corporate updates were announced.
The company announced the start of a global Phase III trial for EscharEx® targeting VLUs.
The FDA approved NexoBrid® for eschar removal in adults with severe burns.
EMA has validated for review the application to expand NexoBrid® indication to pediatric patients.